Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...
Learn how to create burndown charts to track project progress, improve team performance, and download free templates to get ...
Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...
Holding announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback